Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.89 |
| ▸ | CHRNA7 | P36544 | 9/20 | 0.74 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.53 |
| ▸ | HTR3B | O95264 | 4/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459284 | 0.94 | HTR3A (1.00) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1459693 | 0.94 | HTR3A (1.00) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL4938323 | 0.93 | HTR3A (0.98) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL4943294 | 0.93 | HTR3A (0.98) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1459330 | 0.85 | CHRNA7 (1.00) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL6101321 | 0.85 | HTR3A (0.66) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL4940947 | 0.84 | CHRNA7 (1.00) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL6097906 | 0.83 | CHRNA7 (0.63) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL6100386 | 0.81 | HTR3A (0.67) | HTR3ACHRNA7PLK1ALOX15 | |
| SCHEMBL6100380 | 0.81 | HTR3A (0.67) | HTR3ACHRNA7PLK1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | HTR3A 3325/4885CHRNA7 1836/4885HTR3E 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.